DLBCL | Clinical

Tafasitamab/Lenalidomide Combo Demonstrates Favorable Efficacy in DLBCL

July 21, 2021

In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.

Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL

July 15, 2021

Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.

Real World Data Show Patients with DLBCL Receive Axi-Cel/Tisa-Cel Prior to Treatment Failure

June 13, 2021

Real world data looking at the use of the recently approved CAR T-cell therapies tisagenlecleucel and axicabtagene ciloleucel show that patients are receiving it prior to failing treatments and that 1 in 6 patients were experiencing relapse after treatment.

Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCL

June 12, 2021

Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.